Heron Therapeutics, Inc. (HRTX) stock
HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.28−0.00 (-0.74%)
Close on Nov 17, 2026Market cap $53.58MP/E –Yield –
Heron Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Heron Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$8.73M, down 345.5% year over year. For fiscal 2025 it was -$224.00K. The highest annual figure on record is -$224.00K in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$224.00K | – |
| FY2024 | Dec 31, 2024 | -$9.04M | – |
| FY2023 | Dec 31, 2023 | -$107.72M | – |
| FY2022 | Dec 31, 2022 | -$171.77M | – |
| FY2021 | Dec 31, 2021 | -$214.81M | – |
| FY2020 | Dec 31, 2020 | -$225.32M | – |
| FY2019 | Dec 31, 2019 | -$208.65M | – |
| FY2018 | Dec 31, 2018 | -$182.42M | – |
| FY2017 | Dec 31, 2017 | -$193.03M | – |
| FY2016 | Dec 31, 2016 | -$169.82M | – |
| FY2015 | Dec 31, 2015 | -$96.19M | – |
| FY2014 | Dec 31, 2014 | -$73.98M | – |
| FY2013 | Dec 31, 2013 | -$54.12M | – |
| FY2012 | Dec 31, 2012 | -$23.63M | – |
| FY2011 | Dec 31, 2011 | -$10.88M | – |
| FY2010 | Dec 31, 2010 | -$9.71M | – |
| FY2009 | Dec 31, 2009 | -$9.89M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.59M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.24M | -214.3% |
| Q4 FY2025 | Dec 31, 2025 | $575.00K | -87.9% |
| Q3 FY2025 | Sep 30, 2025 | -$3.48M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.03M | – |
| Q1 FY2025 | Mar 31, 2025 | $3.71M | – |
| Q4 FY2024 | Dec 31, 2024 | $4.75M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.88M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.80M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.11M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.51M | – |
| Q3 FY2023 | Sep 30, 2023 | -$24.20M | – |
| Q2 FY2023 | Jun 30, 2023 | -$41.66M | – |
| Q1 FY2023 | Mar 31, 2023 | -$32.35M | – |
| Q4 FY2022 | Dec 31, 2022 | -$19.56M | – |
| Q3 FY2022 | Sep 30, 2022 | -$41.18M | – |
| Q2 FY2022 | Jun 30, 2022 | -$48.83M | – |
| Q1 FY2022 | Mar 31, 2022 | -$62.20M | – |
| Q4 FY2021 | Dec 31, 2021 | -$52.74M | – |
| Q3 FY2021 | Sep 30, 2021 | -$50.95M | – |
| Q2 FY2021 | Jun 30, 2021 | -$59.74M | – |
| Q1 FY2021 | Mar 31, 2021 | -$51.38M | – |
| Q4 FY2020 | Dec 31, 2020 | -$60.58M | – |
| Q3 FY2020 | Sep 30, 2020 | -$57.62M | – |
| Q2 FY2020 | Jun 30, 2020 | -$55.00M | – |
| Q1 FY2020 | Mar 31, 2020 | -$52.11M | – |
| Q4 FY2019 | Dec 31, 2019 | -$58.80M | – |
| Q3 FY2019 | Sep 30, 2019 | -$34.33M | – |
| Q2 FY2019 | Jun 30, 2019 | -$51.29M | – |
| Q1 FY2019 | Mar 31, 2019 | -$64.23M | – |
| Q4 FY2018 | Dec 31, 2018 | -$50.89M | – |
| Q3 FY2018 | Sep 30, 2018 | -$41.40M | – |
| Q2 FY2018 | Jun 30, 2018 | -$38.52M | – |
| Q1 FY2018 | Mar 31, 2018 | -$51.61M | – |
| Q4 FY2017 | Dec 31, 2017 | -$61.51M | – |
| Q3 FY2017 | Sep 30, 2017 | -$40.91M | – |
| Q2 FY2017 | Jun 30, 2017 | -$41.64M | – |
| Q1 FY2017 | Mar 31, 2017 | -$48.97M | – |
| Q4 FY2016 | Dec 31, 2016 | -$46.50M | – |
| Q3 FY2016 | Sep 30, 2016 | -$47.43M | – |
See a number that looks wrong?